Genetic Testing is the analysis of DNA, chromosomes or related genetic material to identify variants associated with disease, disease susceptibility, carrier status, ancestry, reproductive considerations, treatment response or other defined purposes. Clinical genetic testing can examine a single gene, multiple genes, chromosomes, targeted variants or broader genomic regions. Testing may be performed on blood, saliva, tumour tissue or other biological samples depending on whether germline or somatic information is required. The meaning of a result depends on the test design and clinical context. Genetic testing therefore encompasses a wide range of technologies rather than representing one standard procedure.
Germline genetic testing examines inherited genetic information and can identify pathogenic variants associated with hereditary disorders or cancer predisposition. Results may be classified as pathogenic, likely pathogenic, uncertain significance, likely benign or benign according to established evidence frameworks. A pathogenic variant can provide evidence supporting a diagnosis or elevated risk, but the clinical effect depends on the gene and specific disorder.
A negative result can mean that no relevant alteration was detected by the test, but it does not necessarily exclude a genetic cause if the assay cannot detect certain variant types or if the relevant gene has not been identified. Genetic counselling helps explain these distinctions before and after testing.
Carrier testing investigates whether an individual carries a pathogenic variant that can cause a recessive or other inherited condition in offspring when inherited in particular combinations. Prenatal testing examines genetic information during pregnancy, while preimplantation genetic testing can examine embryos in assisted reproductive contexts. Newborn screening tests selected conditions in newborns so that potentially serious disorders can be detected before symptoms develop. These applications differ in purpose, timing, test methodology and ethical considerations. A screening result usually indicates an increased or decreased likelihood rather than establishing a definitive diagnosis, so abnormal screening results may require confirmatory testing.
Genetic Testing can use several technological approaches. Chromosomal analysis can identify large structural or numerical abnormalities, while microarray methods can detect many copy number changes. Polymerase chain reaction can target specific sequences, and sequencing can identify nucleotide level variants across selected genes or broader regions. Multigene panels analyse multiple genes associated with a clinical phenotype, while exome or genome sequencing provides much broader coverage. The broader the test, the greater the possibility of finding incidental or uncertain variants. Test selection should therefore be based on the clinical question rather than assuming that the largest possible test is always the most appropriate.
Somatic genetic testing is widely used in cancer care to examine alterations acquired by tumour cells. Such testing can identify molecular characteristics that support diagnosis, prognosis or selection of targeted treatment. Somatic results are not automatically inherited and should not be interpreted as evidence that relatives carry the same variant. However, some tumour testing can incidentally reveal a variant that may also be germline, in which case confirmatory germline testing may be appropriate. Distinguishing germline from somatic findings is therefore essential. Tumour heterogeneity, sample quality and tumour cell content can also influence the reliability of somatic testing.
Genetic Testing has limitations that must be communicated clearly. A negative result may not exclude disease, particularly when testing has limited coverage or when the causal mechanism is not yet known. A variant of uncertain significance should generally not be used as though it were a confirmed disease causing finding. Test sensitivity depends on the variant type and technology. Large genomic rearrangements, repeat expansions, low level mosaicism and alterations in difficult genomic regions may require specialised methods. Interpretation can also change over time as new research becomes available. Laboratories may therefore periodically reclassify variants, particularly those originally reported as uncertain.
Genetic testing has ethical and practical implications because genetic information can have consequences beyond the individual tested. Results may affect relatives, reproductive decisions, psychological wellbeing, insurance or employment considerations depending on jurisdiction and legal protections. Privacy and data governance are important because genetic information can be uniquely identifying and may be retained in clinical or research databases. Informed consent should explain the purpose and limitations of testing and, where relevant, the possibility of secondary findings. Genetic counselling is particularly valuable when results have significant implications for family members or when interpretation is complex.
A common misconception is that Genetic Testing can predict exactly whether a person will develop a disease. Most genetic findings alter probabilities rather than determine outcomes with certainty, except in some highly penetrant disorders and specific circumstances. Genetic risk also interacts with environmental exposure, age, lifestyle and other biological factors. Another misconception is that a negative test means that genetics have no role in a condition. A test can only address the variants and mechanisms it is designed to detect. Properly used, Genetic Testing can improve diagnosis, identify inherited risk, guide treatment and inform reproductive decisions, but its value depends on appropriate test selection, analytical quality, interpretation and communication of uncertainty.
